Protagonist Therapeutics, Inc. (PTGX) Financial Analysis & Valuation | Quarter Chart
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II cli... more
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based th... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $8.96B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Dinesh V. Patel |
| IPO Date | 2016-08-11 | CAGR | — |
| Employees | 141 | Website | www.protagonist-inc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PTGX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $7.25B | P/E | 134.4 | Forward P/E | -1394.62 | PEG | — |
| P/S | 20.84 | P/B | 7.18 | P/CF | 73.27 | P/FCF | 70.82 |
| Sales | $281.99M | Sales 1Y | 34.81% | Sales 3Y | inf% | Sales 5Y | 936.05% |
| EPS | $1.03 | EPS 1Y | 47.67% | EPS 3Y | -140.54% | EPS 5Y | -153.84% |
| Sales QoQ | 278.72% | EPS QoQ | 4164.43% | Sales QoQ Avg | 244.86% | EPS QoQ Avg | 1020.17% |
| Gross Margin | 99.86% | Operating Margin | 20.69% | Profit Margin | 29.4% | ROCE | 6.88% |
| ROA | 9% | ROE | 12% | Altman Z Score | 115.9 | Piotroski Score | 5 |
| Current Ratio | 21.71 | Quick Ratio | 21.71 | Cash Ratio | 11.3 | Op. CF Ratio | 4.58 |
| Debt/Equity | 0.01 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.32 | Receivables Turnover | 21.02 |
| Enterprise Value | $7.25B | P/E Ratio | 134.4 |
| Forward P/E | -1394.62 | PEG Ratio | — |
| P/S Ratio | 20.84 | P/B Ratio | 7.18 |
| P/CF Ratio | 73.27 | P/FCF Ratio | 70.82 |
| EPS | $1.03 | EPS Growth 1Y | 47.67% |
| EPS Growth 3Y | -140.54% | EPS Growth 5Y | -153.84% |
| Revenue Growth 1Y | 34.81% | Gross Margin | 99.86% |
| Operating Margin | 20.69% | Profit Margin | 29.4% |
| ROE | 12% | ROA | 9% |
| ROCE | 6.88% | Current Ratio | 21.71 |
| Quick Ratio | 21.71 | Cash Ratio | 11.3 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 115.9 | Piotroski Score | 5 |
Protagonist Therapeutics, Inc. (PTGX) valuation & financials
Protagonist Therapeutics, Inc. (PTGX) has a market capitalization of $8.96B and trades at a price-to-earnings ratio of 134.4. It operates in the Healthcare sector (Biotechnology).
Protagonist Therapeutics, Inc.'s revenue grew +34.8% over the last year.
Protagonist Therapeutics, Inc.'s next earnings report is scheduled for November 5, 2026 (provider scheduled date); analysts estimate EPS of $2.39. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)